• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Experimental study of prevention of liver metastases from gastrointestinal cancer by locoregional chemotherapy

Research Project

Project/Area Number 05671096
Research Category

Grant-in-Aid for General Scientific Research (C)

Allocation TypeSingle-year Grants
Research Field Digestive surgery
Research InstitutionSt.Marianna University

Principal Investigator

YAMAMURA Takuya  St.Marianna University, Faculty of Medicine, assistant professor, 医学部, 助教授 (90114701)

Co-Investigator(Kenkyū-buntansha) SEO Keisuke  St.Marianna University, Faculty of Medicine, instructor, 医学部, 助手 (00247363)
AKAISHI Osamu  St.Marianna University, Faculty of Medicine, instructor, 医学部, 助手 (30231799)
Project Period (FY) 1993 – 1995
Project Status Completed (Fiscal Year 1995)
Budget Amount *help
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1995: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1994: ¥300,000 (Direct Cost: ¥300,000)
Fiscal Year 1993: ¥1,000,000 (Direct Cost: ¥1,000,000)
Keywordsgastrointestinal cancer / liver metastasis / continuous intraportal chemotherapy / 5-fluorouracil / cancer suppressor gene / 薬物動態 / 持続門脈内注入療法 / アドリアマイシン
Research Abstract

Efficacy of prevention of liver metastases by continuous intraportal chemotherapy (CIPC) was studied pharmacokinetically and clinically. Relationship between cancer suppressor gene and liver metastases was also studied. Results were as follows : 1) Experimental studies regarding prevention of liver metastases by CIPC of Adriamycin ; regarding difference of commencement of treatment, inhibition of liver metastases was more effective in the group in which treatment starts immediately after inoculationo f tumor cells. Complete inhibition of liver metastases was obtained in case small number oftumor cells was inoculated. Relationship between concentration of Adriamycin and efficacy of inhibition was positive. These results showed that effective prevention of liver metastases was obtained by CIPC in case number of tumor cells was small in portal vein and high concentration of drug was administered in early stage of metastasis formation. 2) Pharmacokinetics of CIPC of 5-fluorouracil (5FU) ; … More concentratino of 5FU in portal vein, concentration of FdUMP and TS inhibition rate in liver were kept high with continuous intraportal infusion of 5FU.TS inhibition rate, concentration of 5FU and FdUMP in liver was increased in proportion to administration dose of 5FU.However, TS inhibition rate showed low level in the extreme high dose administration of 5FU.3) Clinical results of CIPC of 5FU for prevention of liver metastases after resection of colorectal cancer ; Recurrence rate was decreaed 70% by CIPC of 5FU compared with control group. 4) Relationship between overexpression of cancer suppressor gene in colorectal cancer and liver metastases showed positive.
These results showed that CIPC of 5FU was effective for prevention of liver metastases after resection of colorectal cancer clinically and pharmacokinetically. Clinical studies regarding optimal administration dose of 5FU or combination of other drugs with 5FU,relationship between expression of suppressor gene and efficacy of chemotherapy are necessary. Less

Report

(4 results)
  • 1995 Annual Research Report   Final Research Report Summary
  • 1994 Annual Research Report
  • 1993 Annual Research Report
  • Research Products

    (24 results)

All Other

All Publications (24 results)

  • [Publications] 山村卓也: "抗癌剤の持続門脈内注入療法による肝転移抑制の研究" がん治療のあゆみ. 13. 15-22 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] 松崎弘明: "持続門脈内注入療法における5FUの薬物動態の検討" 癌と化学療法. 21. 2121-2123 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] 松崎弘明: "5FU持続門脈内注入療法における血中、組織中濃度の非線形性" 聖マリアンナ医科大学雑誌. 22. 555-565 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] 山村卓也: "経口ロイコボリン錠とUFTによるBiochemical Modulation療法の薬物動態" 癌と化学療法. 22. 245-251 (1995)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Takuya Yamamura, Osamu Akaishi, Akira Hanai, Kenji Katayama: "Experimental studies on prevention of liver metastases by continuous intraportal chemotherapy." Jpn J Cancer Chemother. 18 (11). 1889-1893 (1991)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Takuya Yamamura, Osamu Akaishi, Akira Hanai, Kenji Katayama: "Continuous intraportal chemotherapy for prevention of liver metastases." Reg Cancer Treat. 1-2. 17-21 (1992)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Akira Hanai: "Pharmacokinetic advantage of continuous intraportal 5-FU infusion as locoregional therapy for prevention of liver metastases." St.Marianna Med J. 20. 663-676 (1992)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Takuya Yamamura, Osamu Akaishi, Akira Hanai, Kenji Katayama: "Experimental studies on inhibition of liver metastases by continuous intraportal chemotherapy." J Jpn Soc Cancer Ther. 28 (11). 1761-1769 (1993)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Takuya Yamamura, Kenji Katayama: "Studies on inhibition of liver metastases by continuous intraportal chemotherapy" Advances in Cancer Treatment. 13. 15-22 (1994)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Hiroaki Matsuzaki: "A unique, apparently non-linear kinetics of 5-fluorouracil in continuous intraportal infusion." St.Marianna Med J. 22. 555-565 (1994)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] 山村 卓也: "抗癌剤の持続門脈内注入療法による肝転移抑制の研究" がん治療のあゆみ. 13. 15-22 (1994)

    • Related Report
      1995 Annual Research Report
  • [Publications] 松崎 弘明: "持続門脈内注入療法における5FUの薬物動態の検討" 癌と化学療法. 21. 2121-2123 (1994)

    • Related Report
      1995 Annual Research Report
  • [Publications] 松崎 弘明: "5FU持続門脈内注入法における血中、組織中濃度の非線形性" 聖マリアンナ医科大学雑誌. 22. 555-565 (1994)

    • Related Report
      1995 Annual Research Report
  • [Publications] 山村 卓也: "経口ロイコボリン錠とUFTによるBiochemical Modulation療法の薬物動態" 癌と化学療法. 22. 245-251 (1995)

    • Related Report
      1995 Annual Research Report
  • [Publications] 山村卓也: "大腸癌肝転移に対する5-FU、ロイコボリン併用動注療法の検討" 癌と化学療法. 20. 1516-1519 (1993)

    • Related Report
      1994 Annual Research Report
  • [Publications] 山村卓也: "大腸癌肝転移に対する持続動注療法の検討" 癌の臨床. 39. 33-38 (1993)

    • Related Report
      1994 Annual Research Report
  • [Publications] 山村卓也: "抗癌剤の持続門脈内注入療法による肝転移抑制の研究" がん治療のあゆみ. 13. 15-22 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] 松崎弘明: "持続門脈内注入療法における5-FUの薬物動態の検討" 癌と化学療法. 21. 2121-2123 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] 松崎弘明: "5-FU持続門脈内注入法における血中,組織中濃度の非線形性" 聖マリアンナ医科大学雑誌. 22. 555-565 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] 山村 卓也: "肝転移予防における持続門注療法の有効性についての実験的検討" 癌と化学療法. 18. 1889-1893 (1991)

    • Related Report
      1993 Annual Research Report
  • [Publications] Takuya YAMAMURA: "Continuous intraportal chemotherapy for prevention of liver metastases" Regional Cancer Treatment. 5. 17-21 (1992)

    • Related Report
      1993 Annual Research Report
  • [Publications] 山村 卓也: "抗癌剤の持続門注療法による肝転移予防の実験的検討" 日本癌治療学会誌. 28. 1761-1769 (1993)

    • Related Report
      1993 Annual Research Report
  • [Publications] 花井 彰: "5FU持続門脈内注入における薬物動態" 癌と化学療法. 19. 1536-1539 (1992)

    • Related Report
      1993 Annual Research Report
  • [Publications] 花井 彰: "肝転移予防の肝局所療法としての5FU持続門脈内注入の利点と薬物動態学的解析" 聖マリアンナ医科大学雑誌. 20. 663-676 (1992)

    • Related Report
      1993 Annual Research Report

URL: 

Published: 1993-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi